Crunching the numbers for ABUS... Refresh in a moment for the full analysis.
Arbutus Biopharma Corp (ABUS)
Healthcare
mixed
$4.29
Updated: 2026-04-12
52
TradeApes Score
hold
Financial Strength
55
Mixed
Operating Trend
65
Healthy
Valuation
40
Weak
Capital Allocation
25
Stressed
Risk
80
Strong
Key Findings
+
Strong revenue growth — sales up more than 20% year over year
−
Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.